Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japanese go-ahead for Cortecs' Helisal Helicobacter Pylori test:

This article was originally published in Clinica

Executive Summary

UK company Cortecs has received approval by the Ministry of Health to market its Helisal rapid whole blood Helicobacter pylori test in Japan. Helisal is licensed to Zenyaku Kogyo, which obtained regulatory approval. It will be marketed as Helitest in Japan. H pylori, which is a major cause of duodenal and gastric cancer, is the second most common infection known in man after tooth decay with an estimated 200 million people being infected worldwide. Japan has over 800,000 cases of gastric cancer annually - the highest incidence in the developed world.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT085120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel